Article

Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response

2018-09-20

Abstract excerpt

<h4>Abstract:</h4> <h4>PURPOSE</h4> Measurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in AML. However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer information regarding the chemotherapy sensitivity of the leukemic clone. <h4>PATIENTS AND METHODS</h4> Blood from 45 adult AML patients at day 1 and 4...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 809bfe0c-4ae3-5bdf-878a-498cee79d4f1
DOI: 10.1101/422352

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical responseDOI 10.1101/422352Read

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterSemantic proximity Read

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterSemantic proximity Read

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemiaSemantic proximity Read

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaSemantic proximity Read

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.Semantic proximity Read

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.Semantic proximity Read

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.Semantic proximity Read

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapseSemantic proximity Read

Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNASemantic proximity Read